PIA
ADMA icon

Piedmont Investment Advisors’s ADMA Biologics ADMA Stock Holding History

Piedmont Investment Advisors’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-328
Closed -$1K – 1060
2018
Q2 		$1K Buy
+328
New +$1.64K ﹤0.01% 2720

Other funds holding ADMA

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
BCM
Biomark Capital Management Greenwich, Connecticut $8.9M AUM 97.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
MWVC
Morgens Waterfall Vintiadis & Co New York $81.2M AUM 86.87% 1-Year Est. Return

Piedmont Investment Advisors's ADMA Position: Q3 2018 in Review

Piedmont Investment Advisors sold out of ADMA Biologics (ADMA) in Q3 2018, closing a stake of 328 shares — an estimated $1K sold.

Piedmont Investment Advisors first reported a position in ADMA in Q2 2018 and held it in 1 quarter. The position peaked at $1K in Q2 2018. 58 funds tracked by Wall St. Rank hold ADMA as of Q3 2018.

  • Piedmont Investment Advisors reported no remaining ADMA Biologics position as of Q3 2018 after selling out during the quarter.
  • Piedmont Investment Advisors sold 328 ADMA Biologics shares in Q3 2018, an estimated $1K.
  • Piedmont Investment Advisors first reported a position in ADMA Biologics in Q2 2018 and held it in 1 quarter.
  • Piedmont Investment Advisors's ADMA Biologics position peaked at $1K in Q2 2018.
  • 58 funds tracked by Wall St. Rank held ADMA Biologics as of Q3 2018.

Based on Piedmont Investment Advisors's 13F filing for Q3 2018, filed 8 Nov 2018.